Brief: SynAct Pharma Completes Dosing In Part A Of Combined Phase 2a/b Resolve Study Of Resomelagon (AP1189) In Rheumatoid Arthritis (RA)

SynAct Pharma AB

17/08/2023 06:37

Aug 17 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA COMPLETES DOSING IN PART A OF COMBINED PHASE
2A/B
RESOLVE STUDY OF RESOMELAGON (AP1189) IN RHEUMATOID ARTHRITIS
(RA)
    * PATIENTS NOT SUFFICIENTLY RESPONDING TO FIRST-LINE DISEASE
MODIFYING ANTI-RHEUMATIC DRUGS CONTINUE TO ENDURE SIGNIFICANT
SYMPTOMOLOGY

Source text for Eikon:  ID:nMFN6dsTD7 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))